# Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI

Source: https://onco.cc/trials/nct06343064/  
OnCo record `nct06343064` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Vebreltinib in non-small-cell lung cancer and small-cell lung cancer, run by Avistone Biotechnology Co., Ltd., now recruiting.

## Summary

Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI is a phase 1/2 interventional study registered as NCT06343064 by Avistone Biotechnology Co., Ltd., with 156 participants planned, started 2023-06-13 and due to reach its primary completion in 2026-12-31. Interventions recorded: Vebreltinib, PLB1004. Conditions listed: Non-Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06343064
- Phase: 1/2
- Setting: A Phase Ib/II Study of Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
- Sponsor: Avistone Biotechnology Co., Ltd.
- Enrolled: 156

## Sources

- ClinicalTrials.gov NCT06343064: https://clinicaltrials.gov/study/NCT06343064

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [Vebreltinib](https://onco.cc/drugs/vebreltinib/)
- companies: [Avistone Biotechnology](https://onco.cc/companies/avistone-biotechnology/)

---
JSON: https://onco.cc/api/v1/entities/nct06343064.json